BioSpace News Archive

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the official opening of the second downstream processing suite within the company’s existing Myford North facility.

23andMe Holding Co., a leading consumer genetics and research company, received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada).

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, provided an overview of the Company’s achievements in 2021 and outlined its objectives for 2022.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced preliminary financial results for the fourth quarter and full year 2021.

Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2021 Crysvita® revenue in Ultragenyx territories and Dojolvi® global revenue, cash and investments at year end 2021, and provided 2022 revenue guidance for Crysvita in Ultragenyx territories and Dojolvi globally.

Iovance Biotherapeutics, Inc. today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine.

MiMedx Group, Inc., a transformational placental biologics company, provided a recap of key 2021 accomplishments and outlined strategic milestones planned for 2022.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2021.

AVITA Medical, Inc. announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2021.